Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 2 August 1991:
Vol. 253. no. 5019, pp. 562 - 565
DOI: 10.1126/science.1857987
Prev | Table of Contents | Next

Articles

Science, Vol 253, Issue 5019, 562-565
Copyright © 1991 by American Association for the Advancement of Science

articles

Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides

C Szczylik, T Skorski, NC Nicolaides, L Manzella, L Malaguarnera, D Venturelli, AM Gewirtz, and B Calabretta

Department of Pathology, Temple University Medical School, Philadelphia, PA 19140.

To determine the role of the BCR-ABL gene in the proliferation of blast cells of patients with chronic myelogenous leukemia, leukemia blast cells were exposed to synthetic 18-mer oligodeoxynucleotides complementary to two identified BCR-ABL junctions. Leukemia colony formation was suppressed, whereas granulocyte-macrophage colony formation from normal marrow progenitors was unaffected. When equal proportions of normal marrow progenitors and blast cells were mixed, exposed to the oligodeoxynucleotides, and assayed for residual colony formation, the majority of residual cells were normal. These findings demonstrate the requirement for a functional BCR-ABL gene in maintaining the leukemic phenotype and the feasibility of gene-targeted selective killing of neoplastic cells.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Enhanced Sensitivity of the RET Proto-Oncogene to Ionizing Radiation In vitro.
C. B. Volpato, M. Martinez-Alfaro, R. Corvi, C. Gabus, S. Sauvaigo, P. Ferrari, E. Bonora, A. De Grandi, and G. Romeo (2008)
Cancer Res. 68, 8986-8992
   Abstract »    Full Text »    PDF »
Bcl-2 Antisense Oligonucleotides Are Effective against Systemic but not Central Nervous System Disease in Severe Combined Immunodeficient Mice Bearing Human t(14;18) Follicular Lymphoma.
R. Mohammad, Y. Abubakr, M. Dan, A. Aboukameel, C. Chow, A. Mohamed, N. Hamdy, and A. Al-Katib (2002)
Clin. Cancer Res. 8, 1277-1283
   Abstract »    Full Text »    PDF »
Upstream binding factor up-regulated in hepatocellular carcinoma is related to the survival and cisplatin-sensitivity of cancer cells.
R. HUANG, T. WU, L. XU, A. LIU, Y. JI, and G. HU (2002)
FASEB J 16, 293-301
   Abstract »    Full Text »    PDF »
Pyrrolo-1,5-benzoxazepines Induce Apoptosis in Chronic Myelogenous Leukemia (CML) Cells by Bypassing the Apoptotic Suppressor Bcr-Abl.
M. M. Mc Gee, G. Campiani, A. Ramunno, C. Fattorusso, V. Nacci, M. Lawler, D. C. Williams, and D. M. Zisterer (2001)
J. Pharmacol. Exp. Ther. 296, 31-40
   Abstract »    Full Text »
In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment.
C. Cobaleda and I. Sanchez-Garcia (2000)
Blood 95, 731-737
   Abstract »    Full Text »    PDF »
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL.
C. Perkins, C. N. Kim, G. Fang, and K. N. Bhalla (2000)
Blood 95, 1014-1022
   Abstract »    Full Text »    PDF »
Genetic dissection of dome formation in a mammary cell line: Identification of two genes with opposing action.
I. Zucchi, C. Montagna, L. Susani, R. Montesano, M. Affer, S. Zanotti, E. Redolfi, P. Vezzoni, and R. Dulbecco (1999)
PNAS 96, 13766-13770
   Abstract »    Full Text »    PDF »
2',5'-Oligoadenylate-Antisense Chimeras Cause RNase L to Selectively Degrade bcr/abl mRNA in Chronic Myelogenous Leukemia Cells.
A. Maran, C. F. Waller, J. M. Paranjape, G. Li, W. Xiao, K. Zhang, M. E. Kalaycio, R. K. Maitra, A. E. Lichtin, W. Brugger, et al. (1998)
Blood 92, 4336-4343
   Abstract »    Full Text »    PDF »
Nucleic Acid Therapeutics: State of the Art and Future Prospects.
A. M. Gewirtz, D. L. Sokol, and M. Z. Ratajczak (1998)
Blood 92, 712-736
   Full Text »    PDF »
Improving the Intracellular Delivery and Molecular Efficacy of Antisense Oligonucleotides in Chronic Myeloid Leukemia Cells: A Comparison of Streptolysin-O Permeabilization, Electroporation, and Lipophilic Conjugation.
D. G. Spiller, R. V. Giles, J. Grzybowski, D. M. Tidd, and R. E. Clark (1998)
Blood 91, 4738-4746
   Abstract »    Full Text »    PDF »
BCR-ABL Antisense Oligodeoxynucleotide In Vitro Purging and Autologous Bone Marrow Transplantation for Patients With Chronic Myelogenous Leukemia in Advanced Phase.
P. de Fabritiis, M. C. Petti, E. Montefusco, M. S. De Propris, R. Sala, R. Bellucci, M. Mancini, A. Lisci, F. Bonetto, T. Geiser, et al. (1998)
Blood 91, 3156-3162
   Abstract »    Full Text »    PDF »
Inhibition of BCR-ABL Expression With Antisense Oligodeoxynucleotides Restores beta 1 Integrin-Mediated Adhesion and Proliferation Inhibition in Chronic Myelogenous Leukemia Hematopoietic Progenitors.
R. Bhatia and C. M. Verfaillie (1998)
Blood 91, 3414-3422
   Abstract »    Full Text »    PDF »
The rat gene homologous to the human gene 9-27 is involved in the development of the mammary gland.
I. Zucchi, C. Montagna, L. Susani, P. Vezzoni, and R. Dulbecco (1998)
PNAS 95, 1079-1084
   Abstract »    Full Text »    PDF »
Establishment of a Reproducible Model of Chronic-Phase Chronic Myeloid Leukemia in NOD/SCID Mice Using Blood-Derived Mononuclear or CD34+ Cells.
I. D. Lewis, L. A. McDiarmid, L. M. Samels, L. Bik To, and T. P. Hughes (1998)
Blood 91, 630-640
   Abstract »    Full Text »    PDF »
Gene Therapy for Chronic Myelogenous Leukemia (CML): A Retroviral Vector That Renders Hematopoietic Progenitors Methotrexate-Resistant and CML Progenitors Functionally Normal and Nontumorigenic In Vivo.
R. C.H. Zhao, R. S. McIvor, J. D. Griffin, and C. M. Verfaillie (1997)
Blood 90, 4687-4698
   Abstract »    Full Text »    PDF »
Murine hematopoietic reconstitution after tagging and selection of retrovirally transduced bone marrow cells.
B. Garcia-Hernandez, A. Castellanos, A. Lopez, A. Orfao, and I. Sanchez-Garcia (1997)
PNAS 94, 13239-13244
   Abstract »    Full Text »    PDF »
The antisense bcl-2-IgH transcript is an optimal target for synthetic oligonucleotides.
S. Morelli, D. Delia, S. Capaccioli, A. Quattrone, N. Schiavone, A. Bevilacqua, S. Tomasini, and A. Nicolin (1997)
PNAS 94, 8150-8155
   Abstract »    Full Text »    PDF »
Antisense Oligodeoxyribonucleotides Suppress Hematologic Cell Growth Through Stepwise Release of Deoxyribonucleotides.
J.L. Vaerman, P. Moureau, F. Deldime, P. Lewalle, C. Lammineur, F. Morschhauser, and P. Martiat (1997)
Blood 90, 331-339
   Abstract »    Full Text »    PDF »
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia.
R. Bhatia, C. M. Verfaillie, J. S. Miller, and P. B. McGlave (1997)
Blood 89, 2623-2634
   Full Text »    PDF »
Regulation of the Fas Apoptotic Cell Death Pathway by Abl.
A. J. McGahon, W. K. Nishioka, S. J. Martin, A. Mahboubi, T. G. Cotter, and D. R. Green (1995)
J. Biol. Chem. 270, 22625-22631
   Abstract »    Full Text »    PDF »
Inhibition of High Affinity Basic Fibroblast Growth Factor Binding by Oligonucleotides.
S. M. Fennewald and R. F. Rando (1995)
J. Biol. Chem. 270, 21718-21721
   Abstract »    Full Text »    PDF »
Requirement of B- myb Function for Survival and Differentiative Potential of Human Neuroblastoma Cells.
G. Raschell, A. Negroni, A. Sala, S. Pucci, A. Romeo, and B. Calabretta (1995)
J. Biol. Chem. 270, 8540-8545
   Abstract »    Full Text »    PDF »
The Molecular Basis of Leukemia.
M. J. Cline (1994)
N. Engl. J. Med. 330, 328-336
   Full Text »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)